ProCE Banner Activity

Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma

Conference Coverage

In this exploratory analysis from the CheckMate 76K study, the RFS benefit with nivolumab vs placebo was observed across biomarker subgroups, and a multivariate model found that TMB and IFNγ signature had the greatest independent effect on the relative benefit of nivolumab.

Released: June 09, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc